Interventional Cardiology Devices Market - Global Forecast To 2029
商品番号 : SMB-70812
| 出版社 | MarketsandMarkets |
| 出版年月 | 2024年12月 |
| ページ数 | 368 |
| 図表数 | 441 |
| 価格タイプ | シングルユーザライセンス |
| 価格 | USD 4,950 |
| 種別 | 英文調査報告書 |
Report Overview
The global interventional cardiology devices market is projected to reach USD 27.80 billion in 2024 and is projected to reach USD 37.27 billion by 2029, at a CAGR of 6.0% during the forecast period.
世界の心臓インターベンション装置市場は、2024年に278億米ドルに達すると予測されており、予測期間中のCAGRは6.0%で、2029年までに372億7000万米ドルに達すると予測されています。
The growth of the interventional cardiology devices market is driven by several key factors, most notably the increasing prevalence of cardiovascular diseases (CVD) worldwide, advancements in minimally invasive procedures, and growing demand for improved patient outcomes. As rates of heart disease, hypertension, and diabetes rise, the need for effective treatments such as angioplasty, stenting, and valve replacements also increases. Technological innovations, including the development of drug-eluting stents, bioresorbable scaffolds, and advanced imaging technologies, have enabled safer and more precise procedures, which contribute to the market’s growth.
“Based on the angioplasty balloons type, the old/normal balloons segment is expected to grow by the highest CAGR in the interventional cardiology devices market.”
Traditional angioplasty balloons, also known as plain old balloon angioplasty (POBA), offer several advantages over drug-eluting balloons (DEBs) in certain clinical scenarios. First, traditional balloons tend to be less costly than DEBs, making them a more accessible option for healthcare systems and patients, especially in regions with limited healthcare budgets or where reimbursement policies may not fully cover DEB, also POBA also has a simpler mechanism—it dilates narrowed blood vessels by compressing plaque against the vessel walls without releasing drugs, which can be beneficial in cases where the risks associated with drug delivery aren’t justified. For example, in acute settings like treating certain types of arterial blockages where drug-delivery isn’t critical to outcomes, POBA may provide sufficient clinical results without the added complexity or cost of drug elution.
“The embolic protection devices segment in hemodynamic flow alteration devices segment is expected to grow with the highest CAGR in the interventional cardiology devices market.”
Embolic protection devices (EPDs) are a vital advancement in interventional cardiology, designed to capture and remove debris that may dislodge during vascular procedures, thereby minimizing the risk of embolization. These devices are particularly beneficial during interventions like carotid artery stenting, where dislodged particles could travel to the brain and cause strokes. By capturing such debris, EPDs significantly reduce periprocedural stroke risks and improve the safety profile of these interventions.
“The guidewires segment in other devices segment is expected to grow with the highest CAGR in the interventional cardiology devices market.”
Guidewires are essential in interventional cardiology, offering precision, flexibility, and control that enhance the safety and effectiveness of procedures like angioplasty and stent placement. These thin, flexible wires guide catheters through blood vessels, allowing clinicians to navigate complex vascular structures and reach targeted areas with minimal trauma to surrounding tissues. Their superior torque response and maneuverability help cardiologists access difficult-to-reach lesions, improving procedural success rates and reducing the need for open surgery.
“Based on the end user, hospitals segment is expected to grow by the highest CAGR in the interventional cardiology devices market.
Most interventional cardiology procedures, such as angioplasties, stent placements, and structural heart interventions, are carried out in hospitals because they boast special facilities and the sophisticated imaging technologies that would treat a patient with maximum quality. They are well equipped both for simple and complicated processes with a good staff; besides, they are where they can be managed whenever a complication arises. These settings enable cardiologists to take the latest tool systems into practice, including drug-eluting stents, rotational atherectomy and intravascular ultrasound, to ensure utmost precision and safety for patients.
“Asia Pacific to grow with the highest CAGR in the interventional cardiology devices market during the forecast period.”
The Asia-Pacific region is also expected to experience maximum growth in the interventional cardiology devices market in the next few years due to several key factors. Growth is driven by an increasingly aging population, the growing prevalence of cardiovascular diseases, and increased adoption of minimally invasive procedures, especially in countries such as China, Japan, and India. Increased healthcare expenses and development of health infrastructure promote the availability of high-end interventional cardiology services throughout the region.
The break up of the profile of primary participants in the interventional cardiology devices market:
- By Company Type: Tier 1- 35%, Tier 2- 45%, and Tier 3-20%
- By Designation: C-level Executives- 35%, Directors- 25% , and Others- 40%.
- By Region: North America – 40%, Europe – 30%, APAC –20%, Latin America – 5%,Middle East & Africa–5%
Key players in the interventional cardiology devices market
Some of the prominent players operating in the interventional cardiology devices market include Boston Scientific Corporation (US), Medtronic (US), Abbott (US), B. Braun SE (Germany), Terumo Corporation (Japan), Edwards Lifesciences Corporation (US), Koninklijke Philips N.V. (Netherlands), Integer Holdings Corporation (US), Teleflex Incorporated (US), Penumbra, Inc. (US), Cook (US), Cordis (US), iVascular S.L.U (Spain), Biosensors International Group, Ltd (Singapore), BIOTRONIK SE & Co. KG (Germany), AMG International (Germany), ENDOCOR GmbH (Germany), InSitu Technologies, Inc. (US), Meril Life Sciences (India), Alvimedica (Istanbul), Cardionovum GmBH (Germany), Medinol Ltd (Turkey), Wellinq (Netherlands), Balton SP (Poland), Translumina (India).
Research Coverage:
The report analyzes the interventional cardiology devices market and aims at estimating the market size and future growth potential of this market based on various segments such as angioplasty stents, structural heart devices, catheters, angioplasty balloons, plaque modification devices, hemodynamic flow alteration devices, other devices and end user. The report also includes a product portfolio matrix of various interventional cardiology technologies available in the market. The report also provides a competitive analysis of the key players in this market, along with their company profiles, product offerings, and key market strategies.
Reasons to Buy the Report
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall interventional cardiology devices market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.
This report provides insights into the following pointers:
- Of Analysis of key drivers (growing prevalence of cardiovascular diseases, technological advancements in interventional cardiology procedures, increased prevalence of diabetes & growing product launches by leading players in developing countries), restraints (availability of alternative treatments & recall of products by industry participants to limit the uptake of interventional cardiology equipment), opportunities (high growth potential in emerging markets & growing coronary stent demand in developing countries) and challenges (stringent regulatory requirements delaying the approval of cardiac devices).
- Product Enhancement/Innovation: Comprehensive details about new product launches and anticipated trends in the global interventional cardiology devices market.
- Product Development/Innovation: Detailed insights on upcoming trends, research & development activities, and new product launches in the global interventional cardiology devices market
- Market Development: Comprehensive information on the lucrative emerging markets by angioplasty stents, structural heart devices, catheters, angioplasty balloons, plaque modification devices, hemodynamic flow alteration devices, other devices and end user.
- Market Diversification: Exhaustive information about new product and services or product and service enhancements, growing geographies, recent developments, and investments in the global interventional cardiology devices market.
- Competitive Assessment: Thorough evaluation of the market shares, growth plans, offerings of product and services, and capacities of the major competitors in the global interventional cardiology devices market.
Table of Contents
1 INTRODUCTION 29
1.1 STUDY OBJECTIVES 29
1.2 MARKET DEFINITION 29
1.3 MARKET SCOPE 29
1.3.1 MARKET SEGMENTATION 30
1.3.2 INCLUSIONS & EXCLUSIONS 31
1.3.3 YEARS CONSIDERED 31
1.3.4 CURRENCY CONSIDERED 31
1.4 MARKET STAKEHOLDERS 32
1.5 LIMITATIONS 32
1.6 SUMMARY OF CHANGES 32
2 RESEARCH METHODOLOGY 34
2.1 INTRODUCTION 34
2.1.1 SECONDARY RESEARCH 35
2.1.2 KEY DATA FROM SECONDARY SOURCES 36
2.1.2.1 Primary data 36
2.1.3 KEY DATA FROM PRIMARY SOURCES 38
2.1.3.1 Insights from primary experts 39
2.2 MARKET SIZE ESTIMATION 41
2.3 DATA TRIANGULATION APPROACH 47
2.4 MARKET SHARE ANALYSIS 47
2.5 STUDY ASSUMPTIONS 48
2.6 RESEARCH LIMITATIONS 48
2.6.1 METHODOLOGY-RELATED LIMITATIONS 48
2.7 RISK ASSESSMENT 49
3 EXECUTIVE SUMMARY 50
4 PREMIUM INSIGHTS 56
4.1 INTERVENTIONAL CARDIOLOGY DEVICES MARKET OVERVIEW 56
4.2 ASIA PACIFIC: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY END USER 57
4.3 INTERVENTIONAL CARDIOLOGY DEVICES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 58
4.4 REGIONAL MIX: INTERVENTIONAL CARDIOLOGY DEVICES MARKET (2022–2029) 59
5 MARKET OVERVIEW 60
5.1 INTRODUCTION 60
5.2 MARKET DYNAMICS 60
5.2.1 DRIVERS 61
5.2.1.1 Growing prevalence of cardiovascular diseases 61
5.2.1.2 Rising technological investments in interventional cardiology procedures 62
5.2.1.3 Increasing prevalence of diabetes 63
5.2.1.4 Favorable regulatory support 63
5.2.2 RESTRAINTS 64
5.2.2.1 Availability of alternative treatments 64
5.2.2.2 Product recalls 65
5.2.3 OPPORTUNITIES 65
5.2.3.1 High growth potential in emerging markets 65
5.2.3.2 Increasing demand for coronary stents 66
5.2.4 CHALLENGES 67
5.2.4.1 Stringent regulatory requirements for product approvals 67
5.3 INDUSTRY TRENDS 68
5.3.1 DRUG-ELUTING TECHNOLOGIES 68
5.3.2 INCREASING EMPHASIS ON MINIMALLY INVASIVE PROCEDURES 68
5.4 SUPPLY CHAIN ANALYSIS 69
5.5 VALUE CHAIN ANALYSIS 71
5.6 TECHNOLOGY ANALYSIS 72
5.6.1 KEY TECHNOLOGIES 72
5.6.1.1 TAVR technology 72
5.6.2 ADJACENT TECHNOLOGIES 73
5.6.3 COMPLEMENTARY TECHNOLOGIES 74
5.6.3.1 Integration of real-time monitoring into wearable technologies 74
5.6.3.2 Precise cardiovascular interventions through artificial intelligence 75
5.7 PORTER’S FIVE FORCES ANALYSIS 76
5.7.1 THREAT OF NEW ENTRANTS 77
5.7.2 THREAT OF SUBSTITUTES 77
5.7.3 BARGAINING POWER OF SUPPLIERS 77
5.7.4 BARGAINING POWER OF BUYERS 77
5.7.5 INTENSITY OF COMPETITIVE RIVALRY 78
5.8 REGULATORY LANDSCAPE 78
5.8.1 REGULATORY ANALYSIS 78
5.8.1.1 North America 78
5.8.1.1.1 US 78
5.8.1.2 Europe 79
5.8.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 80
5.9 PRICING ANALYSIS 83
5.9.1 INDICATIVE AVERAGE SELLING PRICE OF KEY PLAYERS, BY PRODUCT TYPE, 2023 83
5.9.2 INDICATIVE AVERAGE SELLING PRICE OF INTERVENTIONAL CARDIOLOGY DEVICES, BY PRODUCT TYPE, 2023 84
5.9.3 INDICATIVE AVERAGE SELLING PRICE, BY REGION 84
5.10 ECOSYSTEM ANALYSIS 85
5.11 PATENT ANALYSIS 87
5.11.1 PATENT PUBLICATION TRENDS FOR INTERVENTIONAL CARDIOLOGY DEVICES 87
5.11.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS 87
5.12 TRADE ANALYSIS 90
5.12.1 TRADE ANALYSIS FOR INTERVENTIONAL CARDIOLOGY DEVICES AND CONSUMABLES 90
5.12.2 HS CODES 90
5.13 KEY CONFERENCES & EVENTS, 2024−2025 92
5.14 KEY STAKEHOLDERS & BUYING CRITERIA 93
5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS 93
5.14.2 BUYING CRITERIA 94
5.15 UNMET NEEDS/END-USER EXPECTATIONS 95
5.16 IMPACT OF AI/GEN AI ON INTERVENTIONAL CARDIOLOGY DEVICES MARKET 96
5.17 CASE STUDY ANALYSIS 96
5.17.1 CASE STUDY 1: BOSTON SCIENTIFIC CORPORATION USES GUIDEZILLA II EXTENSION CATHETER FOR PC INTERVENTIONS 96
5.17.2 CASE STUDY 2: MEDTRONIC PROVIDES CARDIOLOGY DEVICES FOR VENOUS INTERVENTIONS 97
5.17.3 CASE STUDY 3: ABOTT OFFERS DRUG-ELUTING STENTS FOR PATIENTS WITH HIGHER RISK OF STROKE 97
5.18 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 98
5.19 ADJACENT MARKETS FOR INTERVENTIONAL CARDIOLOGY DEVICES 99
5.20 INVESTMENT & FUNDING SCENARIO 99
6 ANGIOPLASTY STENTS MARKET, BY TYPE 100
6.1 INTRODUCTION 101
6.1.1 DRUG-ELUTING STENTS 103
6.1.1.1 Drug-eluting stents to hold largest share of angioplasty stents market 103
6.1.2 BARE-METAL STENTS 105
6.1.2.1 Increasing use of drug-eluting stents to limit growth of bare-metal stents market 105
6.1.3 BIOABSORBABLE STENTS 107
6.1.3.1 Ability of bioabsorbable stents to ensure complete healing of arteries to propel demand 107
7 STRUCTURAL HEART DEVICES MARKET, BY TYPE 109
7.1 INTRODUCTION 110
7.1.1 AORTIC VALVE THERAPY DEVICES 111
7.1.1.1 Increasing prevalence of aortic valve stenosis to support market growth 111
7.1.2 OTHER THERAPY DEVICES 113
8 CATHETERS MARKET, BY TYPE 116
8.1 INTRODUCTION 117
8.1.1 ANGIOGRAPHY CATHETERS 119
8.1.1.1 Rising cases of artery disease and heart attacks to propel market 119
8.1.2 GUIDING CATHETERS 121
8.1.2.1 Increasing number of angiography procedures to drive the market 121
8.1.3 IVUS/OCT CATHETERS 123
8.1.3.1 Ability to obtain 3D images for aneurysm assessment to support market growth 123
9 ANGIOPLASTY BALLOONS MARKET, BY TYPE 126
9.1 INTRODUCTION 127
9.1.1 OLD/NORMAL BALLOONS 128
9.1.1.1 Low treatment costs associated with old/normal balloons to drive growth 128
9.1.2 DRUG-ELUTING BALLOONS 130
9.1.2.1 Rising number of regulatory approvals for drug-eluting balloons to support market growth during forecast period 130
9.1.3 CUTTING/SCORING BALLOONS 132
9.1.3.1 Limited use of cutting balloon-aided procedures to restrain market growth 132
10 PLAQUE MODIFICATION DEVICES MARKET, BY TYPE 134
10.1 INTRODUCTION 135
10.1.1 THROMBECTOMY DEVICES 137
10.1.1.1 Ability to remove blood clots in STEMI and NSTEMI patients to propel market 137
10.1.2 ATHERECTOMY DEVICES 138
10.1.2.1 Increasing use of lipid-modifying drugs for atherosclerosis to support market growth 138
11 HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE 140
11.1 INTRODUCTION 141
11.1.1 EMBOLIC PROTECTION DEVICES 142
11.1.1.1 Adoption of filter & occlusion-based devices to propel market 142
11.1.2 CHRONIC TOTAL OCCLUSION DEVICES 144
11.1.2.1 Uptake in treatment of total occlusions to drive market 144
12 OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE 145
12.1 INTRODUCTION 146
12.1.1 GUIDEWIRES 147
12.1.1.1 Growing demand for stent placements and coronary intervention procedures to propel market 147
12.1.2 VASCULAR CLOSURE DEVICES 149
12.1.2.1 Ability to provide increased efficacy in patient outcomes to fuel uptake 149
12.1.3 INTRODUCER SHEATHS 150
12.1.3.1 Ability to provide secure access to blood vessels to support market growth 150
12.1.4 BALLOON INFLATION DEVICES 151
12.1.4.1 Increasing incidence of peripheral artery disease to drive market 151
12.1.5 HEMOSTASIS HEART VALVES 153
12.1.5.1 Growing focus on precision medicine 153
13 INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY END USER 154
13.1 INTRODUCTION 155
13.2 HOSPITALS 155
13.2.1 AVAILABILITY OF ADVANCED INFRASTRUCTURE AND SPECIALIZED EQUIPMENT TO DRIVE MARKET 155
13.3 AMBULATORY SURGERY CENTERS 157
13.3.1 LOW CASES OF HAIS AND SHORTER RECOVERY TIMES TO PROPEL MARKET 157
13.4 OTHER END USERS 159
14 INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY REGION 160
14.1 INTRODUCTION 161
14.2 NORTH AMERICA 162
14.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 162
14.2.2 US 167
14.2.2.1 Availability of reimbursements for cardiology procedures to drive market 167
14.2.3 CANADA 171
14.2.3.1 Rising prevalence of chronic diseases to drive market 171
14.3 EUROPE 175
14.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 176
14.3.2 GERMANY 180
14.3.2.1 Growing hub for advanced technology product distributors to drive market 180
14.3.3 FRANCE 184
14.3.3.1 Favorable government initiatives in France to support market growth 184
14.3.4 UK 188
14.3.4.1 Growing focus on personalized medicine to fuel uptake 188
14.3.5 ITALY 192
14.3.5.1 Increasing cases of obesity and CVD to support market growth 192
14.3.6 SPAIN 196
14.3.6.1 Increasing prevalence of age-related CVD conditions to drive market 196
14.3.7 REST OF EUROPE 200
14.4 ASIA PACIFIC 204
14.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 204
14.4.2 CHINA 209
14.4.2.1 High tobacco consumption and increasing cases of CVD to fuel uptake 209
14.4.3 JAPAN 213
14.4.3.1 Increasing demand for stents and catheters to support market growth 213
14.4.4 INDIA 217
14.4.4.1 Improvements in angioplasty devices to fuel uptake 217
14.4.5 AUSTRALIA 221
14.4.5.1 Increasing cases of lifestyle disorders to support market growth 221
14.4.6 SOUTH KOREA 225
14.4.6.1 Growth in pharmaceutical sectors to propel market 225
14.4.7 REST OF ASIA PACIFIC 229
14.5 LATIN AMERICA 233
14.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 233
14.5.2 BRAZIL 237
14.5.2.1 Rising demand for quality treatment and focus on growing healthcare infrastructure to drive market 237
14.5.3 MEXICO 241
14.5.3.1 Increasing cases of diabetes to fuel market 241
14.5.4 REST OF LATIN AMERICA 245
14.6 MIDDLE EAST & AFRICA 249
14.6.1 MIDDLE EAST & AFRICA: MACROECONOMIC OUTLOOK 249
14.6.2 GCC COUNTRIES 253
14.6.3 REST OF MIDDLE EAST & AFRICA 257
15 COMPETITIVE LANDSCAPE 262
15.1 OVERVIEW 262
15.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 262
15.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN INTERVENTIONAL CARDIOLOGY DEVICES MARKET 263
15.3 REVENUE ANALYSIS 264
15.4 MARKET SHARE ANALYSIS 265
15.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 268
15.5.1 STARS 268
15.5.2 EMERGING LEADERS 268
15.5.3 PERVASIVE PLAYERS 268
15.5.4 PARTICIPANTS 268
15.6 COMPANY FOOTPRINT 270
15.6.1 COMPANY FOOTPRINT: KEY PLAYERS, 2023 270
15.6.1.1 Company footprint 270
15.6.1.2 Region footprint 271
15.6.1.3 Product footprint 272
15.6.1.4 Angioplasty stents footprint 274
15.6.1.5 Structural heart devices footprint 275
15.6.1.6 Catheters footprint 276
15.6.1.7 Angioplasty balloons footprint 277
15.6.1.8 Plaque modification devices footprint 278
15.6.1.9 Hemodynamic flow alteration devices footprint 279
15.6.1.10 Other interventional cardiology devices footprint 280
15.6.1.11 End-user footprint 281
15.7 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 282
15.7.1 PROGRESSIVE COMPANIES 282
15.7.2 RESPONSIVE COMPANIES 282
15.7.3 DYNAMIC COMPANIES 282
15.7.4 STARTING BLOCKS 282
15.7.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023 284
15.8 COMPANY VALUATION & FINANCIAL METRICS 286
15.8.1 FINANCIAL METRICS 286
15.8.2 COMPANY VALUATION 286
15.9 BRAND/PRODUCT COMPARATIVE ANALYSIS 287
15.10 R&D ASSESSMENT OF KEY PLAYERS 288
15.11 COMPETITIVE SCENARIO 288
15.11.1 PRODUCT LAUNCHES & APPROVALS 288
15.11.2 DEALS 289
15.11.3 EXPANSIONS 290
16 COMPANY PROFILES 291
16.1 KEY PLAYERS 291
16.1.1 BOSTON SCIENTIFIC CORPORATION 291
16.1.1.1 Business overview 291
16.1.1.2 Products offered 292
16.1.1.3 Recent developments 295
16.1.1.3.1 Product launches & approvals 295
16.1.1.3.2 Deals 296
16.1.1.4 MnM view 297
16.1.1.4.1 Key strengths 297
16.1.1.4.2 Strategic choices 297
16.1.1.4.3 Weaknesses & competitive threats 297
16.1.2 MEDTRONIC 298
16.1.2.1 Business overview 298
16.1.2.2 Products offered 299
16.1.2.3 Recent developments 302
16.1.2.3.1 Product launches & approvals 302
16.1.2.3.2 Deals 303
16.1.2.4 MnM view 303
16.1.2.4.1 Key strengths 303
16.1.2.4.2 Strategic choices 303
16.1.2.4.3 Weaknesses & competitive threats 303
16.1.3 ABBOTT 304
16.1.3.1 Business overview 304
16.1.3.2 Products offered 305
16.1.3.3 Recent developments 307
16.1.3.3.1 Product launches & approvals 307
16.1.3.3.2 Deals 308
16.1.3.4 MnM view 308
16.1.3.4.1 Key strengths 308
16.1.3.4.2 Strategic choices 308
16.1.3.4.3 Weaknesses & competitive threats 308
16.1.4 KONINKLIJKE PHILIPS N.V. 309
16.1.4.1 Business overview 309
16.1.4.2 Products offered 310
16.1.4.3 Recent developments 311
16.1.4.3.1 Deals 311
16.1.5 TERUMO CORPORATION 312
16.1.5.1 Business overview 312
16.1.5.2 Products offered 313
16.1.5.3 Recent developments 315
16.1.5.3.1 Product launches 315
16.1.5.3.2 Expansions 315
16.1.5.4 MnM view 315
16.1.5.4.1 Key strengths 315
16.1.5.4.2 Strategic choices 315
16.1.5.4.3 Weaknesses & competitive threats 316
16.1.6 EDWARDS LIFESCIENCES CORPORATION 317
16.1.6.1 Business overview 317
16.1.6.2 Products offered 318
16.1.6.3 Recent developments 319
16.1.6.3.1 Product launches & approvals 319
16.1.6.3.2 Deals 320
16.1.7 B. BRAUN SE 321
16.1.7.1 Business overview 321
16.1.7.2 Products offered 322
16.1.7.3 Recent developments 324
16.1.7.3.1 Product launches & approvals 324
16.1.7.3.2 Deals 324
16.1.8 INTEGER HOLDINGS CORPORATION 325
16.1.8.1 Business overview 325
16.1.8.2 Products offered 326
16.1.8.3 Recent developments 327
16.1.8.3.1 Deals 327
16.1.8.3.2 Expansions 328
16.1.9 TELEFLEX INCORPORATED 329
16.1.9.1 Business overview 329
16.1.9.2 Products offered 330
16.1.9.3 Recent developments 331
16.1.9.3.1 Product approvals 331
16.1.10 PENUMBRA, INC. 333
16.1.10.1 Business overview 333
16.1.10.2 Products offered 334
16.1.10.3 Recent developments 335
16.1.10.3.1 Product launches & approvals 335
16.1.11 COOK 336
16.1.11.1 Business overview 336
16.1.11.2 Products offered 336
16.1.11.3 Recent developments 338
16.1.11.3.1 Deals 338
16.1.12 CORDIS 339
16.1.12.1 Business overview 339
16.1.12.2 Products offered 339
16.1.12.3 Recent developments 340
16.1.12.3.1 Product launches & approvals 340
16.1.12.3.2 Deals 340
16.1.13 IVASCULAR S.L.U. 341
16.1.13.1 Business overview 341
16.1.13.2 Products offered 341
16.1.14 BIOSENSORS INTERNATIONAL GROUP, LTD. 342
16.1.14.1 Business overview 342
16.1.14.2 Products offered 342
16.1.14.3 Recent developments 343
16.1.14.3.1 Product launches 343
16.1.15 BIOTRONIK SE & CO. KG 344
16.1.15.1 Business overview 344
16.1.15.2 Products offered 344
16.1.15.3 Recent developments 345
16.1.15.3.1 Product launches 345
16.2 OTHER PLAYERS 346
16.2.1 AMG INTERNATIONAL (SUBSIDIARY OF Q3 MEDICAL) 346
16.2.2 ENDOCOR GMBH & CO. KG 347
16.2.3 INSITU TECHNOLOGIES, INC. 348
16.2.4 MERIL LIFE SCIENCES PVT. LTD 349
16.2.5 ALVIMEDICA 350
16.2.6 CARDIONOVUM GMBH 351
16.2.7 MEDINOL 352
16.2.8 WELLINQ 353
16.2.9 BALTON SP. 354
16.2.10 TRANSLUMINA 355
17 APPENDIX 356
17.1 DISCUSSION GUIDE 356
17.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 362
17.3 CUSTOMIZATION OPTIONS 364
17.4 RELATED REPORTS 364
17.5 AUTHOR DETAILS 365
LIST OF TABLES
TABLE 1 INCLUSIONS & EXCLUSIONS 31
TABLE 2 STANDARD CURRENCY CONVERSION RATES (UNIT OF USD) 32
TABLE 3 INTERVENTIONAL CARDIOLOGY DEVICES MARKET: STUDY ASSUMPTIONS 48
TABLE 4 RISK ASSESSMENT ANALYSIS: INTERVENTIONAL CARDIOLOGY DEVICES MARKET 49
TABLE 5 GLOBAL ANNUAL CARDIAC SURGICAL VOLUMES PER 100,000 POPULATION (2023) 62
TABLE 6 DIABETIC POPULATION, BY REGION, 2019 VS. 2030 63
TABLE 7 KEY COMPANIES INVOLVED IN PROVIDING DRUG-ELUTING TECHNOLOGIES 68
TABLE 8 BENEFITS OF TAVR OVER SAVR: PATIENT’S PERSPECTIVE 69
TABLE 9 COMPANIES PROVIDING FFR TECHNOLOGIES 73
TABLE 10 INTERVENTIONAL CARDIOLOGY DEVICES MARKET: PORTER’S FIVE FORCES ANALYSIS 76
TABLE 11 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 80
TABLE 12 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 80
TABLE 13 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 81
TABLE 14 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 82
TABLE 15 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 82
TABLE 16 INDICATIVE AVERAGE SELLING PRICE OF KEY PLAYERS, BY TYPE 83
TABLE 17 INDICATIVE AVERAGE SELLING PRICE OF INTERVENTIONAL CARDIOLOGY DEVICES, BY REGION, 2023 85
TABLE 18 INTERVENTIONAL CARDIOLOGY DEVICES MARKET: ROLE IN ECOSYSTEM 85
TABLE 19 LIST OF PATENTS/PATENT APPLICATIONS IN THE INTERVENTIONAL CARDIOLOGY DEVICES MARKET, 2021–2023 89
TABLE 20 IMPORT DATA FOR INTERVENTIONAL CARDIOLOGY DEVICES, BY COUNTRY (2023) 90
TABLE 21 EXPORT DATA FOR INTERVENTIONAL CARDIOLOGY DEVICES, BY COUNTRY (2023) 91
TABLE 22 INTERVENTIONAL CARDIOLOGY DEVICES MARKET: DETAILED LIST OF CONFERENCES & EVENTS 92
TABLE 23 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP 3 END USERS 93
TABLE 24 KEY BUYING CRITERIA FOR TOP 3 END USERS 94
TABLE 25 INTERVENTIONAL CARDIOLOGY DEVICES MARKET: UNMET NEEDS/END-USER EXPECTATIONS 95
TABLE 26 INTERVENTIONAL CARDIOLOGY DEVICES MARKET: IMPACT OF GEN AI 96
TABLE 27 INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY PRODUCT TYPE,
2022–2029 (USD MILLION) 101
TABLE 28 ANGIOPLASTY STENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 102
TABLE 29 ANGIOPLASTY STENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 102
TABLE 30 DRUG-ELUTING ANGIOPLASTY STENTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 104
TABLE 31 DRUG-ELUTING ANGIOPLASTY STENTS MARKET, BY REGION,
2022–2029 (THOUSAND UNITS) 105
TABLE 32 BARE-METAL ANGIOPLASTY STENTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 106
TABLE 33 BARE-METAL ANGIOPLASTY STENTS MARKET, BY REGION,
2022–2029 (THOUSAND UNITS) 107
TABLE 34 BIOABSORBABLE ANGIOPLASTY STENTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 108
TABLE 35 STRUCTURAL HEART DEVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 110
TABLE 36 STRUCTURAL HEART DEVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 111
TABLE 37 AORTIC VALVE THERAPY DEVICES MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 112
TABLE 38 AORTIC VALVE THERAPY DEVICES MARKET, BY REGION,
2022–2029 (THOUSAND UNITS) 113
TABLE 39 OTHER THERAPY DEVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 114
TABLE 40 OTHER THERAPY DEVICES MARKET, BY REGION, 2022–2029 (THOUSAND UNITS) 115
TABLE 41 CATHETERS MARKET, BY TYPE, 2022–2029 (USD MILLION) 117
TABLE 42 CATHETERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 118
TABLE 43 ANGIOGRAPHY CATHETERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 120
TABLE 44 ANGIOGRAPHY CATHETERS MARKET, BY REGION, 2022–2029 (THOUSAND UNITS) 121
TABLE 45 GUIDING CATHETERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 122
TABLE 46 GUIDING CATHETERS MARKET, BY REGION, 2022–2029 (THOUSAND UNITS) 123
TABLE 47 IVUS/OCT CATHETERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 124
TABLE 48 IVUS/OCT CATHETERS MARKET, BY REGION, 2022–2029 (THOUSAND UNITS) 125
TABLE 49 ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2022–2029 (USD MILLION) 127
TABLE 50 ANGIOPLASTY BALLOONS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 128
TABLE 51 OLD/NORMAL ANGIOPLASTY BALLOONS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 129
TABLE 52 DRUG-ELUTING ANGIOPLASTY BALLOONS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 131
TABLE 53 DRUG-ELUTING ANGIOPLASTY BALLOONS MARKET, BY REGION,
2022–2029 (THOUSAND UNITS) 132
TABLE 54 CUTTING/SCORING ANGIOPLASTY BALLOONS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 133
TABLE 55 PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 135
TABLE 56 PLAQUE MODIFICATION DEVICES MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 136
TABLE 57 PROCEDURE DATA FOR PLAQUE MODIFICATION DEVICES, BY REGION,
2023 (MILLION) 137
TABLE 58 THROMBECTOMY DEVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 138
TABLE 59 ATHERECTOMY DEVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 139
TABLE 60 HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 141
TABLE 61 HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 142
TABLE 62 EMBOLIC PROTECTION DEVICES MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 143
TABLE 63 CHRONIC TOTAL OCCLUSION DEVICES MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 144
TABLE 64 OTHER DEVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 146
TABLE 65 OTHER DEVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 147
TABLE 66 GUIDEWIRES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 148
TABLE 67 VASCULAR CLOSURE DEVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 149
TABLE 68 INTRODUCER SHEATHS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 151
TABLE 69 BALLOON INFLATION DEVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 152
TABLE 70 HEMOSTASIS HEART VALVES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 153
TABLE 71 INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY END USER,
2022–2029 (USD MILLION) 155
TABLE 72 INTERVENTIONAL CARDIOLOGY DEVICES MARKET FOR HOSPITALS,
BY COUNTRY, 2022–2029 (USD MILLION) 156
TABLE 73 INTERVENTIONAL CARDIOLOGY DEVICES MARKET FOR AMBULATORY SURGERY CENTERS, BY COUNTRY, 2022–2029 (USD MILLION) 158
TABLE 74 INTERVENTIONAL CARDIOLOGY DEVICES MARKET FOR OTHER END USERS,
BY COUNTRY, 2022–2029 (USD MILLION) 159
TABLE 75 INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY REGION,
2022–2029 (USD MILLION) 162
TABLE 76 NORTH AMERICA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET,
BY COUNTRY, 2022–2029 (USD MILLION) 164
TABLE 77 NORTH AMERICA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET,
BY PRODUCT TYPE, 2022–2029 (USD MILLION) 164
TABLE 78 NORTH AMERICA: ANGIOPLASTY STENTS MARKET, BY TYPE,
2022–2029 (USD MILLION) 165
TABLE 79 NORTH AMERICA: STRUCTURAL HEART DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 165
TABLE 80 NORTH AMERICA: CATHETERS MARKET, BY TYPE, 2022–2029 (USD MILLION) 165
TABLE 81 NORTH AMERICA: ANGIOPLASTY BALLOONS MARKET, BY TYPE,
2022–2029 (USD MILLION) 166
TABLE 82 NORTH AMERICA: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 166
TABLE 83 NORTH AMERICA: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET,
BY TYPE, 2022–2029 (USD MILLION) 166
TABLE 84 NORTH AMERICA: OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET,
BY TYPE, 2022–2029 (USD MILLION) 167
TABLE 85 NORTH AMERICA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET,
BY END USER, 2022–2029 (USD MILLION) 167
TABLE 86 US: MACROECONOMIC INDICATORS 168
TABLE 87 US: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY PRODUCT TYPE,
2022–2029 (USD MILLION) 168
TABLE 88 US: ANGIOPLASTY STENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 169
TABLE 89 US: STRUCTURAL HEART DEVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 169
TABLE 90 US: CATHETERS MARKET, BY TYPE, 2022–2029 (USD MILLION) 169
TABLE 91 US: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2022–2029 (USD MILLION) 170
TABLE 92 US: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 170
TABLE 93 US: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 170
TABLE 94 INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 171
TABLE 95 US: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY END USER,
2022–2029 (USD MILLION) 171
TABLE 96 CANADA: MACROECONOMIC INDICATORS 172
TABLE 97 CANADA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY PRODUCT TYPE, 2022–2029 (USD MILLION) 172
TABLE 98 CANADA: ANGIOPLASTY STENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 173
TABLE 99 CANADA: STRUCTURAL HEART DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 173
TABLE 100 CANADA: CATHETERS MARKET, BY TYPE, 2022–2029 (USD MILLION) 173
TABLE 101 CANADA: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2022–2029 (USD MILLION) 174
TABLE 102 CANADA: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 174
TABLE 103 CANADA: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 174
TABLE 104 CANADA: OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET,
BY TYPE, 2022–2029 (USD MILLION) 175
TABLE 105 CANADA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY END USER,
2022–2029 (USD MILLION) 175
TABLE 106 EUROPE: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 176
TABLE 107 EUROPE: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY PRODUCT TYPE, 2022–2029 (USD MILLION) 177
TABLE 108 EUROPE: ANGIOPLASTY STENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 177
TABLE 109 EUROPE: STRUCTURAL HEART DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 178
TABLE 110 EUROPE: CATHETERS MARKET, BY TYPE, 2022–2029 (USD MILLION) 178
TABLE 111 EUROPE: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2022–2029 (USD MILLION) 178
TABLE 112 EUROPE: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 179
TABLE 113 EUROPE: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 179
TABLE 114 EUROPE: OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 179
TABLE 115 EUROPE: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY END USER,
2022–2029 (USD MILLION) 180
TABLE 116 GERMANY: MACROECONOMIC INDICATORS 180
TABLE 117 GERMANY: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY PRODUCT TYPE, 2022–2029 (USD MILLION) 181
TABLE 118 GERMANY: ANGIOPLASTY STENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 181
TABLE 119 GERMANY: STRUCTURAL HEART DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 182
TABLE 120 GERMANY: CATHETERS MARKET, BY TYPE, 2022–2029 (USD MILLION) 182
TABLE 121 GERMANY: ANGIOPLASTY BALLOONS MARKET, BY TYPE,
2022–2029 (USD MILLION) 182
TABLE 122 GERMANY: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 183
TABLE 123 GERMANY: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 183
TABLE 124 GERMANY: OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 183
TABLE 125 GERMANY: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY END USER, 2022–2029 (USD MILLION) 184
TABLE 126 FRANCE: MACROECONOMIC INDICATORS 184
TABLE 127 FRANCE: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY PRODUCT TYPE, 2022–2029 (USD MILLION) 185
TABLE 128 FRANCE: ANGIOPLASTY STENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 185
TABLE 129 FRANCE: STRUCTURAL HEART DEVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 186
TABLE 130 FRANCE: CATHETERS MARKET, BY TYPE, 2022–2029 (USD MILLION) 186
TABLE 131 FRANCE: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2022–2029 (USD MILLION) 186
TABLE 132 FRANCE: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 187
TABLE 133 FRANCE: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 187
TABLE 134 FRANCE: OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET,
BY TYPE, 2022–2029 (USD MILLION) 187
TABLE 135 FRANCE: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY END USER,
2022–2029 (USD MILLION) 188
TABLE 136 UK: MACROECONOMIC INDICATORS 188
TABLE 137 UK: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY PRODUCT TYPE,
2022–2029 (USD MILLION) 189
TABLE 138 UK: ANGIOPLASTY STENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 189
TABLE 139 UK: STRUCTURAL HEART DEVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 190
TABLE 140 UK: CATHETERS MARKET, BY TYPE, 2022–2029 (USD MILLION) 190
TABLE 141 UK: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2022–2029 (USD MILLION) 190
TABLE 142 UK: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 191
TABLE 143 UK: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 191
TABLE 144 UK: OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 191
TABLE 145 UK: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY END USER,
2022–2029 (USD MILLION) 192
TABLE 146 ITALY: MACROECONOMIC INDICATORS 192
TABLE 147 ITALY: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY PRODUCT TYPE, 2022–2029 (USD MILLION) 193
TABLE 148 ITALY: ANGIOPLASTY STENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 193
TABLE 149 ITALY: STRUCTURAL HEART DEVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 194
TABLE 150 ITALY: CATHETERS MARKET, BY TYPE, 2022–2029 (USD MILLION) 194
TABLE 151 ITALY: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2022–2029 (USD MILLION) 194
TABLE 152 ITALY: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 195
TABLE 153 ITALY: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 195
TABLE 154 ITALY: OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 195
TABLE 155 ITALY: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY END USER,
2022–2029 (USD MILLION) 196
TABLE 156 SPAIN: MACROECONOMIC INDICATORS 197
TABLE 157 SPAIN: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY PRODUCT TYPE, 2022–2029 (USD MILLION) 197
TABLE 158 SPAIN: ANGIOPLASTY STENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 197
TABLE 159 SPAIN: STRUCTURAL HEART DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 198
TABLE 160 SPAIN: CATHETERS MARKET, BY TYPE, 2022–2029 (USD MILLION) 198
TABLE 161 SPAIN: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2022–2029 (USD MILLION) 198
TABLE 162 SPAIN: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 199
TABLE 163 SPAIN: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 199
TABLE 164 SPAIN: OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 199
TABLE 165 SPAIN: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY END USER,
2022–2029 (USD MILLION) 200
TABLE 166 REST OF EUROPE: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY PRODUCT TYPE, 2022–2029 (USD MILLION) 201
TABLE 167 REST OF EUROPE; ANGIOPLASTY STENTS MARKET, BY TYPE,
2022–2029 (USD MILLION) 201
TABLE 168 REST OF EUROPE: STRUCTURAL HEART DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 202
TABLE 169 REST OF EUROPE: CATHETERS MARKET, BY TYPE, 2022–2029 (USD MILLION) 202
TABLE 170 REST OF EUROPE: ANGIOPLASTY BALLOONS MARKET, BY TYPE,
2022–2029 (USD MILLION) 202
TABLE 171 REST OF EUROPE: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 203
TABLE 172 REST OF EUROPE: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET,
BY TYPE, 2022–2029 (USD MILLION) 203
TABLE 173 REST OF EUROPE: OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET,
BY TYPE, 2022–2029 (USD MILLION) 203
TABLE 174 REST OF EUROPE: INTERVENTIONAL CARDIOLOGY DEVICES MARKET,
BY END USER, 2022–2029 (USD MILLION) 204
TABLE 175 ASIA PACIFIC: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 206
TABLE 176 ASIA PACIFIC: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY PRODUCT TYPE, 2022–2029 (USD MILLION) 206
TABLE 177 ASIA PACIFIC: ANGIOPLASTY STENTS MARKET, BY TYPE,
2022–2029 (USD MILLION) 207
TABLE 178 ASIA PACIFIC: STRUCTURAL HEART DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 207
TABLE 179 ASIA PACIFIC: CATHETERS MARKET, BY TYPE, 2022–2029 (USD MILLION) 207
TABLE 180 ASIA PACIFIC: ANGIOPLASTY BALLOONS MARKET, BY TYPE,
2022–2029 (USD MILLION) 208
TABLE 181 ASIA PACIFIC: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 208
TABLE 182 ASIA PACIFIC: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET,
BY TYPE, 2022–2029 (USD MILLION) 208
TABLE 183 ASIA PACIFIC: OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET,
BY TYPE, 2022–2029 (USD MILLION) 209
TABLE 184 ASIA PACIFIC: INTERVENTIONAL CARDIOLOGY DEVICES MARKET,
BY END USER, 2022–2029 (USD MILLION) 209
TABLE 185 CHINA: MACROECONOMIC INDICATORS 210
TABLE 186 CHINA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY PRODUCT TYPE, 2022–2029 (USD MILLION) 210
TABLE 187 CHINA: ANGIOPLASTY STENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 211
TABLE 188 CHINA: STRUCTURAL HEART DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 211
TABLE 189 CHINA: CATHETERS MARKET, BY TYPE, 2022–2029 (USD MILLION) 211
TABLE 190 CHINA: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2022–2029 (USD MILLION) 212
TABLE 191 CHINA: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 212
TABLE 192 CHINA: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET,
BY TYPE, 2022–2029 (USD MILLION) 212
TABLE 193 CHINA: OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 213
TABLE 194 CHINA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY END USER,
2022–2029 (USD MILLION) 213
TABLE 195 JAPAN: MACROECONOMIC INDICATORS 214
TABLE 196 JAPAN: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY PRODUCT TYPE, 2022–2029 (USD MILLION) 214
TABLE 197 JAPAN: ANGIOPLASTY STENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 215
TABLE 198 JAPAN: STRUCTURAL HEART DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 215
TABLE 199 JAPAN CATHETERS MARKET, BY TYPE, 2022–2029 (USD MILLION) 215
TABLE 200 JAPAN: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2022–2029 (USD MILLION) 216
TABLE 201 JAPAN: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 216
TABLE 202 JAPAN: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 216
TABLE 203 JAPAN: OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 217
TABLE 204 JAPAN: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY END USER,
2022–2029 (USD MILLION) 217
TABLE 205 INDIA: MACROECONOMIC INDICATORS 218
TABLE 206 INDIA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY PRODUCT TYPE, 2022–2029 (USD MILLION) 218
TABLE 207 INDIA: ANGIOPLASTY STENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 219
TABLE 208 INDIA: STRUCTURAL HEART DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 219
TABLE 209 INDIA: CATHETERS MARKET, BY TYPE, 2022–2029 (USD MILLION) 219
TABLE 210 INDIA: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2022–2029 (USD MILLION) 220
TABLE 211 INDIA: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 220
TABLE 212 INDIA: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 220
TABLE 213 INDIA: OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 221
TABLE 214 INDIA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY END USER,
2022–2029 (USD MILLION) 221
TABLE 215 AUSTRALIA: MACROECONOMIC INDICATORS 222
TABLE 216 AUSTRALIA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY PRODUCT TYPE, 2022–2029 (USD MILLION) 222
TABLE 217 AUSTRALIA: ANGIOPLASTY STENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 223
TABLE 218 AUSTRALIA: STRUCTURAL HEART DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 223
TABLE 219 AUSTRALIA: CATHETERS MARKET, BY TYPE, 2022–2029 (USD MILLION) 223
TABLE 220 AUSTRALIA: ANGIOPLASTY BALLOONS MARKET, BY TYPE,
2022–2029 (USD MILLION) 224
TABLE 221 AUSTRALIA: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 224
TABLE 222 AUSTRALIA: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET,
BY TYPE, 2022–2029 (USD MILLION) 224
TABLE 223 AUSTRALIA: OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET,
BY TYPE, 2022–2029 (USD MILLION) 225
TABLE 224 AUSTRALIA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY END USER, 2022–2029 (USD MILLION) 225
TABLE 225 SOUTH KOREA: MACROECONOMIC INDICATORS 226
TABLE 226 SOUTH KOREA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY PRODUCT TYPE, 2022–2029 (USD MILLION) 226
TABLE 227 SOUTH KOREA: ANGIOPLASTY STENTS MARKET, BY TYPE,
2022–2029 (USD MILLION) 227
TABLE 228 SOUTH KOREA: STRUCTURAL HEART DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 227
TABLE 229 SOUTH KOREA: CATHETERS MARKET, BY TYPE, 2022–2029 (USD MILLION) 227
TABLE 230 SOUTH KOREA: ANGIOPLASTY BALLOONS MARKET, BY TYPE,
2022–2029 (USD MILLION) 228
TABLE 231 SOUTH KOREA: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 228
TABLE 232 SOUTH KOREA: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET,
BY TYPE, 2022–2029 (USD MILLION) 228
TABLE 233 SOUTH KOREA: OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET,
BY TYPE, 2022–2029 (USD MILLION) 229
TABLE 234 SOUTH KOREA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET,
BY END USER, 2022–2029 (USD MILLION) 229
TABLE 235 REST OF ASIA PACIFIC: INTERVENTIONAL CARDIOLOGY DEVICES MARKET,
BY PRODUCT TYPE, 2022–2029 (USD MILLION) 230
TABLE 236 REST OF ASIA PACIFIC: ANGIOPLASTY STENTS MARKET, BY TYPE,
2022–2029 (USD MILLION) 230
TABLE 237 REST OF ASIA PACIFIC: STRUCTURAL HEART DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 231
TABLE 238 REST OF ASIA PACIFIC: CATHETERS MARKET, BY TYPE, 2022–2029 (USD MILLION) 231
TABLE 239 REST OF ASIA PACIFIC: ANGIOPLASTY BALLOONS MARKET, BY TYPE,
2022–2029 (USD MILLION) 231
TABLE 240 REST OF ASIA PACIFIC: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 232
TABLE 241 REST OF ASIA PACIFIC: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET,
BY TYPE, 2022–2029 (USD MILLION) 232
TABLE 242 REST OF ASIA PACIFIC: OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 232
TABLE 243 REST OF ASIA PACIFIC: INTERVENTIONAL CARDIOLOGY DEVICES MARKET,
BY END USER, 2022–2029 (USD MILLION) 233
TABLE 244 LATIN AMERICA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 234
TABLE 245 LATIN AMERICA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY PRODUCT TYPE, 2022–2029 (USD MILLION) 234
TABLE 246 LATIN AMERICA: ANGIOPLASTY STENTS MARKET, BY TYPE,
2022–2029 (USD MILLION) 235
TABLE 247 LATIN AMERICA: STRUCTURAL HEART DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 235
TABLE 248 LATIN AMERICA: CATHETERS MARKET, BY TYPE, 2022–2029 (USD MILLION) 235
TABLE 249 LATIN AMERICA: ANGIOPLASTY BALLOONS MARKET, BY TYPE,
2022–2029 (USD MILLION) 236
TABLE 250 LATIN AMERICA: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 236
TABLE 251 LATIN AMERICA: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET,
BY TYPE, 2022–2029 (USD MILLION) 236
TABLE 252 LATIN AMERICA: OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET,
BY TYPE, 2022–2029 (USD MILLION) 237
TABLE 253 LATIN AMERICA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET,
BY END USER, 2022–2029 (USD MILLION) 237
TABLE 254 BRAZIL: MACROECONOMIC INDICATORS 238
TABLE 255 BRAZIL: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY PRODUCT TYPE, 2022–2029 (USD MILLION) 238
TABLE 256 BRAZIL: ANGIOPLASTY STENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 239
TABLE 257 BRAZIL: STRUCTURAL HEART DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 239
TABLE 258 BRAZIL: CATHETERS MARKET, BY TYPE, 2022–2029 (USD MILLION) 239
TABLE 259 BRAZIL: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2022–2029 (USD MILLION) 240
TABLE 260 BRAZIL: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 240
TABLE 261 BRAZIL: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 240
TABLE 262 BRAZIL: OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 241
TABLE 263 BRAZIL: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY END USER,
2022–2029 (USD MILLION) 241
TABLE 264 MEXICO: MACROECONOMIC INDICATORS 242
TABLE 265 MEXICO: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY PRODUCT TYPE, 2022–2029 (USD MILLION) 242
TABLE 266 MEXICO: ANGIOPLASTY STENTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 243
TABLE 267 MEXICO: STRUCTURAL HEART DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 243
TABLE 268 MEXICO: CATHETERS MARKET, BY TYPE, 2022–2029 (USD MILLION) 243
TABLE 269 MEXICO: ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2022–2029 (USD MILLION) 244
TABLE 270 MEXICO: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 244
TABLE 271 MEXICO: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 244
TABLE 272 MEXICO: OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET,
BY TYPE, 2022–2029 (USD MILLION) 245
TABLE 273 MEXICO: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY END USER,
2022–2029 (USD MILLION) 245
TABLE 274 REST OF LATIN AMERICA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET,
BY PRODUCT TYPE, 2022–2029 (USD MILLION) 246
TABLE 275 REST OF LATIN AMERICA: ANGIOPLASTY STENTS MARKET, BY TYPE,
2022–2029 (USD MILLION) 246
TABLE 276 REST OF LATIN AMERICA: STRUCTURAL HEART DEVICES MARKET,
BY TYPE, 2022–2029 (USD MILLION) 247
TABLE 277 REST OF LATIN AMERICA: CATHETERS MARKET, BY TYPE,
2022–2029 (USD MILLION) 247
TABLE 278 REST OF LATIN AMERICA: ANGIOPLASTY BALLOONS MARKET, BY TYPE,
2022–2029 (USD MILLION) 247
TABLE 279 REST OF LATIN AMERICA: PLAQUE MODIFICATION DEVICES MARKET,
BY TYPE, 2022–2029 (USD MILLION) 248
TABLE 280 REST OF LATIN AMERICA: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 248
TABLE 281 REST OF LATIN AMERICA: OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 248
TABLE 282 REST OF LATIN AMERICA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET,
BY END USER, 2022–2029 (USD MILLION) 249
TABLE 283 MIDDLE EAST & AFRICA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET,
BY COUNTRY, 2022–2029 (USD MILLION) 250
TABLE 284 MIDDLE EAST & AFRICA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET,
BY PRODUCT TYPE, 2022–2029 (USD MILLION) 250
TABLE 285 MIDDLE EAST & AFRICA: ANGIOPLASTY STENTS MARKET, BY TYPE,
2022–2029 (USD MILLION) 251
TABLE 286 MIDDLE EAST & AFRICA: STRUCTURAL HEART DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 251
TABLE 287 MIDDLE EAST & AFRICA: CATHETERS MARKET, BY TYPE,
2022–2029 (USD MILLION) 251
TABLE 288 MIDDLE EAST & AFRICA: ANGIOPLASTY BALLOONS MARKET, BY TYPE,
2022–2029 (USD MILLION) 252
TABLE 289 MIDDLE EAST & AFRICA: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 252
TABLE 290 MIDDLE EAST & AFRICA: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET,
BY TYPE, 2022–2029 (USD MILLION) 252
TABLE 291 MIDDLE EAST & AFRICA: OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 253
TABLE 292 MIDDLE EAST & AFRICA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET,
BY END USER, 2022–2029 (USD MILLION) 253
TABLE 293 GCC COUNTRIES: INTERVENTIONAL CARDIOLOGY DEVICES MARKET,
BY PRODUCT TYPE, 2022–2029 (USD MILLION) 254
TABLE 294 GCC COUNTRIES: ANGIOPLASTY STENTS MARKET, BY TYPE,
2022–2029 (USD MILLION) 254
TABLE 295 GCC COUNTRIES: STRUCTURAL HEART DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 255
TABLE 296 GCC COUNTRIES: CATHETERS MARKET, BY TYPE, 2022–2029 (USD MILLION) 255
TABLE 297 GCC COUNTRIES: ANGIOPLASTY BALLOONS MARKET, BY TYPE,
2022–2029 (USD MILLION) 255
TABLE 298 GCC COUNTRIES: PLAQUE MODIFICATION DEVICES MARKET, BY TYPE,
2022–2029 (USD MILLION) 256
TABLE 299 GCC COUNTRIES: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET,
BY TYPE, 2022–2029 (USD MILLION) 256
TABLE 300 GCC COUNTRIES: OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET,
BY TYPE, 2022–2029 (USD MILLION) 256
TABLE 301 GCC COUNTRIES: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY END USER, 2022–2029 (USD MILLION) 257
TABLE 302 REST OF MIDDLE EAST & AFRICA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY PRODUCT TYPE, 2022–2029 (USD MILLION) 258
TABLE 303 REST OF MIDDLE EAST & AFRICA: ANGIOPLASTY STENTS MARKET, BY TYPE,
2022–2029 (USD MILLION) 258
TABLE 304 REST OF MIDDLE EAST & AFRICA: STRUCTURAL HEART DEVICES MARKET,
BY TYPE, 2022–2029 (USD MILLION) 259
TABLE 305 REST OF MIDDLE EAST & AFRICA: CATHETERS MARKET, BY TYPE,
2022–2029 (USD MILLION) 259
TABLE 306 REST OF MIDDLE EAST & AFRICA: ANGIOPLASTY BALLOONS MARKET,
BY TYPE, 2022–2029 (USD MILLION) 259
TABLE 307 REST OF MIDDLE EAST & AFRICA: PLAQUE MODIFICATION DEVICES MARKET,
BY TYPE, 2022–2029 (USD MILLION) 260
TABLE 308 REST OF MIDDLE EAST & AFRICA: HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 260
TABLE 309 REST OF MIDDLE EAST & AFRICA: OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE, 2022–2029 (USD MILLION) 260
TABLE 310 REST OF MIDDLE EAST & AFRICA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY END USER, 2022–2029 (USD MILLION) 261
TABLE 311 OVERVIEW OF STRATEGIES DEPLOYED BY KEY MANUFACTURING COMPANIES 263
TABLE 312 INTERVENTIONAL CARDIOLOGY DEVICES MARKET: DEGREE OF COMPETITION 266
TABLE 313 REGION FOOTPRINT 271
TABLE 314 INTERVENTIONAL CARDIOLOGY DEVICES MARKET: PRODUCT FOOTPRINT 272
TABLE 315 ANGIOPLASTY STENTS FOOTPRINT 274
TABLE 316 STRUCTURAL HEART DEVICES FOOTPRINT 275
TABLE 317 CATHETERS FOOTPRINT 276
TABLE 318 ANGIOPLASTY BALLOONS FOOTPRINT 277
TABLE 319 PLAQUE MODIFICATION DEVICES FOOTPRINT 278
TABLE 320 HEMODYNAMIC FLOW ALTERATION DEVICES FOOTPRINT 279
TABLE 321 OTHER INTERVENTIONAL CARDIOLOGY DEVICES FOOTPRINT 280
TABLE 322 END-USER FOOTPRINT 281
TABLE 323 INTERVENTIONAL CARDIOLOGY DEVICES MARKET: DETAILED LIST OF KEY START-UPS/SMES 284
TABLE 324 INTERVENTIONAL CARDIOLOGY DEVICES MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES 285
TABLE 325 INTERVENTIONAL CARDIOLOGY DEVICES MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–OCTOBER 2024 288
TABLE 326 INTERVENTIONAL CARDIOLOGY DEVICES MARKET: DEALS, JANUARY 2021– OCTOBER 2024 289
TABLE 327 INTERVENTIONAL CARDIOLOGY DEVICES MARKET: EXPANSIONS, JANUARY 2021–OCTOBER 2024 290
TABLE 328 BOSTON SCIENTIFIC CORPORATION: COMPANY OVERVIEW 291
TABLE 329 BOSTON SCIENTIFIC CORPORATION: PRODUCTS OFFERED 292
TABLE 330 BOSTON SCIENTIFIC CORPORATION: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–OCTOBER 2024 295
TABLE 331 BOSTON SCIENTIFIC CORPORATION: DEALS, JANUARY 2021−OCTOBER 2024 296
TABLE 332 MEDTRONIC: COMPANY OVERVIEW 298
TABLE 333 MEDTRONIC: PRODUCTS OFFERED 299
TABLE 334 MEDTRONIC: PRODUCT APPROVALS, JANUARY 2021–OCTOBER 2024 302
TABLE 335 MEDTRONIC: DEALS, JANUARY 2021–OCTOBER 2024 303
TABLE 336 ABBOTT: COMPANY OVERVIEW 304
TABLE 337 ABBOTT: PRODUCTS OFFERED 305
TABLE 338 ABBOTT: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021−OCTOBER 2024 307
TABLE 339 ABBOTT: DEALS, JANUARY 2021−OCTOBER 2024 308
TABLE 340 KONINKLIJKE PHILIPS N.V.: COMPANY OVERVIEW 309
TABLE 341 KONINKLIJKE PHILIPS N.V.: PRODUCTS OFFERED 310
TABLE 342 KONINKLIJKE PHILIPS N.V.: DEALS, JANUARY 2021−OCTOBER 2024 311
TABLE 343 TERUMO CORPORATION: COMPANY OVERVIEW 312
TABLE 344 TERUMO CORPORATION: PRODUCTS OFFERED 313
TABLE 345 TERUMO CORPORATION: PRODUCT LAUNCHES, JANUARY 2021–OCTOBER 2024 315
TABLE 346 TERUMO CORPORATION.: EXPANSIONS, JANUARY 2021−OCTOBER 2024 315
TABLE 347 EDWARDS LIFESCIENCES CORPORATION: COMPANY OVERVIEW 317
TABLE 348 EDWARDS LIFESCIENCES CORPORATION: PRODUCTS OFFERED 318
TABLE 349 EDWARDS LIFESCIENCES CORPORATION: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021−OCTOBER 2024 319
TABLE 350 EDWARDS LIFESCIENCES CORPORATION: DEALS, JANUARY 2021−OCTOBER 2024 320
TABLE 351 B. BRAUN SE: COMPANY OVERVIEW 321
TABLE 352 B. BRAUN SE: PRODUCTS OFFERED 322
TABLE 353 B. BRAUN SE: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021−
OCTOBER 2024 324
TABLE 354 B. BRAUN SE: DEALS, JANUARY 2021−OCTOBER 2024 324
TABLE 355 INTEGER HOLDINGS CORPORATION: COMPANY OVERVIEW 325
TABLE 356 INTEGER HOLDINGS CORPORATION: PRODUCTS OFFERED 326
TABLE 357 INTEGER HOLDINGS CORPORATION.: DEALS, JANUARY 2021−OCTOBER 2024 327
TABLE 358 INTEGER HOLDINGS CORPORATION: EXPANSIONS, JANUARY 2021−
OCTOBER 2024 328
TABLE 359 TELEFLEX INCORPORATED: COMPANY OVERVIEW 329
TABLE 360 TELEFLEX INCORPORATED: PRODUCTS OFFERED 330
TABLE 361 TELEFLEX INCORPORATED: PRODUCT APPROVALS, JANUARY 2021−
OCTOBER 2024 331
TABLE 362 PENUMBRA, INC.: COMPANY OVERVIEW 333
TABLE 363 PENUMBRA, INC: PRODUCTS OFFERED 334
TABLE 364 PENUMBRA, INC: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021−
OCTOBER 2024 335
TABLE 365 COOK: COMPANY OVERVIEW 336
TABLE 366 COOK: PRODUCTS OFFERED 336
TABLE 367 COOK: DEALS, JANUARY 2021–OCTOBER 2024 338
TABLE 368 CORDIS: COMPANY OVERVIEW 339
TABLE 369 CORDIS.: PRODUCTS OFFERED 339
TABLE 370 CORDIS: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021−OCTOBER 2024 340
TABLE 371 CORDIS: DEALS, JANUARY 2021−OCTOBER 2024 340
TABLE 372 IVASCULAR S.L.U.: COMPANY OVERVIEW 341
TABLE 373 IVASCULAR S.L.U: PRODUCTS OFFERED 341
TABLE 374 BIOSENSORS INTERNATIONAL GROUP, LTD.: COMPANY OVERVIEW 342
TABLE 375 BIOSENSORS INTERNATIONAL GROUP, LTD.: PRODUCTS OFFERED 342
TABLE 376 BIOSENSORS INTERNATIONAL GROUP, LTD: PRODUCT LAUNCHES, JANUARY 2021−OCTOBER 2024 343
TABLE 377 BIOTRONIK SE & CO. KG: COMPANY OVERVIEW 344
TABLE 378 BIOTRONIK SE & CO. KG: PRODUCTS OFFERED 344
TABLE 379 BIOTRONIK SE & CO. KG: PRODUCT LAUNCHES, JANUARY 2021−OCTOBER 2024 345
LIST OF FIGURES
FIGURE 1 INTERVENTIONAL CARDIOLOGY DEVICES MARKET SEGMENTATION 30
FIGURE 2 RESEARCH DESIGN 34
FIGURE 3 PRIMARY SOURCES 37
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND OTHER PARTICIPANTS 40
FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION,
AND REGION 40
FIGURE 6 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY END USER, DESIGNATION, AND REGION 41
FIGURE 7 MARKET SIZE APPROACH – REVENUE SHARE ANALYSIS 42
FIGURE 8 REVENUE SHARE ANALYSIS ILLUSTRATION: MEDTRONIC (2023) 42
FIGURE 9 TOP-DOWN APPROACH 43
FIGURE 10 SUPPLY-SIDE ANALYSIS: INTERVENTIONAL CARDIOLOGY DEVICES MARKET (2023) 45
FIGURE 11 CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 46
FIGURE 12 CAGR PROJECTIONS 46
FIGURE 13 DATA TRIANGULATION METHODOLOGY 47
FIGURE 14 ANGIOPLASTY STENTS MARKET, BY TYPE, 2024 VS. 2029 (USD MILLION) 50
FIGURE 15 STRUCTURAL HEART DEVICES MARKET, BY TYPE, 2024 VS. 2029 (USD MILLION) 51
FIGURE 16 CATHETERS MARKET, BY TYPE, 2024 VS. 2029 (USD MILLION) 51
FIGURE 17 ANGIOPLASTY BALLOONS MARKET, BY TYPE, 2024 VS. 2029 (USD MILLION) 52
FIGURE 18 PLAQUE MODIFICATION DEVICES MARKET, BY TYPE,
2024 VS. 2029 (USD MILLION) 52
FIGURE 19 HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE,
2024 VS. 2029 (USD MILLION) 53
FIGURE 20 OTHER DEVICES MARKET, BY TYPE, 2024 VS. 2029 (USD MILLION) 54
FIGURE 21 INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY END USER,
2024 VS. 2029 (USD MILLION) 54
FIGURE 22 GEOGRAPHIC SNAPSHOT OF INTERVENTIONAL CARDIOLOGY DEVICES MARKET 55
FIGURE 23 INCREASING PREVALENCE OF CVD AND DIABETES TO PROPEL MARKET 56
FIGURE 24 HOSPITALS ACCOUNTED FOR LARGEST MARKET SHARE IN CHINA FOR 2023 57
FIGURE 25 CHINA TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD 58
FIGURE 26 ASIA PACIFIC MARKET TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD 59
FIGURE 27 INTERVENTIONAL CARDIOLOGY DEVICES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 60
FIGURE 28 INTERVENTIONAL CARDIOLOGY DEVICES MARKET: SUPPLY CHAIN ANALYSIS 70
FIGURE 29 INTERVENTIONAL CARDIOLOGY DEVICES MARKET: VALUE CHAIN ANALYSIS 71
FIGURE 30 INTERVENTIONAL CARDIOLOGY DEVICES MARKET: PORTER’S FIVE FORCES ANALYSIS 76
FIGURE 31 INDICATIVE AVERAGE SELLING PRICE TREND OF INTERVENTIONAL CARDIOLOGY DEVICES, BY PRODUCT TYPE, 2023 84
FIGURE 32 INTERVENTIONAL CARDIOLOGY DEVICES MARKET: ECOSYSTEM MAP 86
FIGURE 33 PATENT PUBLICATION TRENDS (JANUARY 2013–OCTOBER 2024) 87
FIGURE 34 TOP APPLICANTS & OWNERS (COMPANIES/INSTITUTIONS) FOR INTERVENTIONAL CARDIOLOGY DEVICES PATENTS (JANUARY 2013–OCTOBER 2024) 88
FIGURE 35 TOP APPLICANT COUNTRIES/REGIONS FOR INTERVENTIONAL CARDIOLOGY DEVICES PATENTS (JANUARY 2013–OCTOBER 2024) 89
FIGURE 36 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP 3 END USERS 93
FIGURE 37 KEY BUYING CRITERIA FOR TOP 3 END USERS 94
FIGURE 38 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES IN INTERVENTIONAL CARDIOLOGY DEVICES MARKET 98
FIGURE 39 INTERVENTIONAL CARDIOLOGY DEVICES: ADJACENT MARKETS 99
FIGURE 40 INVESTMENT/VENTURE CAPITAL SCENARIO IN INTERVENTIONAL CARDIOLOGY DEVICES MARKET, 2019–2024 99
FIGURE 41 INTERVENTIONAL CARDIOLOGY DEVICES MARKET: GEOGRAPHIC SNAPSHOT (2023) 161
FIGURE 42 NORTH AMERICA: INTERVENTIONAL CARDIOLOGY DEVICES MARKET SNAPSHOT 163
FIGURE 43 ASIA PACIFIC: INTERVENTIONAL CARDIOLOGY DEVICES MARKET SNAPSHOT 205
FIGURE 44 REVENUE ANALYSIS OF KEY PLAYERS IN INTERVENTIONAL CARDIOLOGY DEVICES MARKET (2019−2023) 265
FIGURE 45 MARKET SHARE ANALYSIS, BY KEY PLAYER (2023) 266
FIGURE 46 INTERVENTIONAL CARDIOLOGY DEVICES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023 269
FIGURE 47 INTERVENTIONAL CARDIOLOGY DEVICES MARKET: COMPANY FOOTPRINT 270
FIGURE 48 INTERVENTIONAL CARDIOLOGY MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023 283
FIGURE 49 EV/EBITDA OF KEY VENDORS 286
FIGURE 50 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 286
FIGURE 51 INTERVENTIONAL CARDIOLOGY DEVICES MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 287
FIGURE 52 R&D ASSESSMENT OF KEY PLAYERS IN INTERVENTIONAL CARDIOLOGY DEVICES MARKET, 2021–2023 288
FIGURE 53 BOSTON SCIENTIFIC CORPORATION: COMPANY SNAPSHOT (2023) 292
FIGURE 54 MEDTRONIC: COMPANY SNAPSHOT (2023) 299
FIGURE 55 ABBOTT: COMPANY SNAPSHOT (2023) 305
FIGURE 56 KONINKLIJKE PHILIPS N.V.: COMPANY SNAPSHOT (2023) 310
FIGURE 57 TERUMO CORPORATION: COMPANY SNAPSHOT (2023) 313
FIGURE 58 EDWARDS LIFESCIENCES CORPORATION: COMPANY SNAPSHOT (2023) 318
FIGURE 59 B. BRAUN SE: COMPANY SNAPSHOT (2023) 322
FIGURE 60 INTEGER HOLDINGS CORPORATION: COMPANY SNAPSHOT (2023) 326
FIGURE 61 TELEFLEX INCORPORATED: COMPANY SNAPSHOT (2023) 330
FIGURE 62 PENUMBRA, INC.: COMPANY SNAPSHOT (2023) 334
MarketsandMarkets（マーケッツアンドマーケッツ）は世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。広範な市場を対象にした市場調査レポートを出版しています。
※MarketsandMarketsの調査レポートはほぼ全タイトルご注文後、最短3時間～12時間以内（営業日基準）にご納品可能です。
ライセンス別価格表
調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。
ライセンスタイプ1
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD4,950 | USD6,650 | USD8,150 | USD10,000 |
ライセンスタイプ2
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD7,150 | USD8,500 | USD9,650 | USD11,000 |
ライセンスタイプ3
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD8,150 | お問合せください | お問合せください | お問合せください |
ライセンスタイプ4
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD9,000 | USD10,500 | USD12,000 | USD13,500 |
ミニレポート ※定性調査にフォーカスした調査レポートです。詳細はお問合せください。
| シングルユーザ | コーポレート |
| USD 2,650 | USD 4,250 |
ご購入に関するご案内
価格・納期について
- 価格
- ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
- ライセンス
- シングルユーザライセンス
- 1名のみレポートファイルのご利用が可能です。
- マルチユーザライセンス
- 同一企業内（関連会社除く）5名までレポートファイルのご利用が可能です。
- コーポレートライセンス
- 同一企業および100％持株会社間・人数無制限でレポートファイルのご利用が可能です。
- エンタープライズサイトライセンス
- 特別ライセンスです。適用範囲についてはお問合せください。
- シングルユーザライセンス
- 納品形態
- Eメール
- 納期
- 最短3時間以内にご納品可能です。通常ご注文後24時間以内（営業日基準）
ご注文方法
- レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。
その他
- 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。
株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。
最新調査レポート
- 自動車用アラミド繊維市場規模、シェア、動向、2030年までの世界予測 2025-12-15
- ポリヒドロキシアルカノエート (PHA) 市場規模、シェア、動向、2030年までの世界予測 2025-12-15
- 複合輸送市場規模、シェア、動向、2032年までの世界予測 2025-12-12
- 有機酸市場規模、シェア、動向、2030年までの世界予測 2025-12-11
- ハイブリッドボンディング市場規模、シェア、動向、2032年までの世界予測 2025-12-11